New court documents have revealed the marketing tactics for OxyContin. The documents are from the lawsuit filed by Massachusetts against Purdue Pharma, the maker of the painkiller. They detail the company’s strategy of reducing the negative reputational effects of overdoses on the brand by pushing blame onto patients and by conducting aggressive marketing to doctors. (STAT)

Walgreens is partnering with Microsoft to develop digital strategies to deliver healthcare. The companies will focus on virtually connecting people with Walgreens stores and providing services from preventative care to chronic disease management. The research deal will run for seven years. (Reuters)

Allergan is pushing for its Restasis patent case to be taken up by the Supreme Court. The pharma company was accused of trying to shift its Restasis patents to the Saint Regis Mohawk Tribe in an attempt to shield the patents from an administrative review. Lower courts have ruled against Allergan and the Mohawk tribe, but its attorneys are hoping the Supreme Court will add the case to its calendar. (Endpoints)

Attorney General nominee William Barr said on Tuesday that he would reconsider the decision to not defend the Affordable Care Act in court. Last summer, the Justice Department said it would not defend the ACA in a lawsuit brought by red states. In his confirmation hearings, Barr said he “would like to review” that position. (Reuters)

The FDA has detailed its plans to keep up with increased cell and gene therapy applications. By 2020, FDA Commissioner Scott Gottlieb and Center for Biologics Evaluation and Research Director Peter Marks said they expect more than 200 applications annually. To keep up, the FDA is planning to add more reviewers to staff, use accelerated approval pathways, and issue guidance to help these drug applications move quickly. (Endpoints)